A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

NCT ID: NCT02603432

Last Updated: 2024-03-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-25

Study Completion Date

2023-03-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urothelial Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Avelumab plus Best Supportive Care (BSC)

Group Type EXPERIMENTAL

Avelumab

Intervention Type BIOLOGICAL

1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

Best Supportive Care

Intervention Type OTHER

BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.

Arm B

Best Supportive Care (BSC) alone

Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the "watch and wait" part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued.

Group Type OTHER

Best Supportive Care

Intervention Type OTHER

BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.

Following the planned interim analysis for this study: Avelumab

Intervention Type BIOLOGICAL

1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avelumab

1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

Intervention Type BIOLOGICAL

Best Supportive Care

BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.

Intervention Type OTHER

Following the planned interim analysis for this study: Avelumab

1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed, unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium
* Stage IV disease at the start of first-line chemotherapy
* Measurable disease (per RECIST v1.1) prior to the start of first-line chemotherapy
* Prior first-line chemotherapy must have consisted of at least 4 cycles and no more than 6 cycles of gemcitabine + cisplatin and/or gemcitabine + carboplatin
* No evidence of progressive disease following completion of first-line chemotherapy (i.e., ongoing CR, PR, or SD per RECIST v1.1 guidelines )

Exclusion Criteria

* Prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization
* Prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA 4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
* Persisting toxicity related to prior therapy (Grade \>1 NCI CTCAE v4.0); however, alopecia, sensory neuropathy (Grade 2 or less), or other (Grade 2 or less) adverse events not constituting a safety risk based on the investigator's judgement are acceptable.
* Patients with known symptomatic central nervous system (CNS) metastases requiring steroids
* Diagnosis of any other malignancy within 5 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anschutz Cancer Center Pavilion Pharmacy

Aurora, Colorado, United States

Site Status

University of Colorado Cancer Center

Aurora, Colorado, United States

Site Status

University of Colorado Denver, CTO (CTRC)

Aurora, Colorado, United States

Site Status

University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

Aurora, Colorado, United States

Site Status

University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

Aurora, Colorado, United States

Site Status

Smilow Cancer Hospital at Yale New Haven

New Haven, Connecticut, United States

Site Status

Smilow Cancer Hospital at Yale-New Haven

New Haven, Connecticut, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

University of Minnesota Medical Center

Minneapolis, Minnesota, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Cleveland Clinic Taussing Cancer Center

Cleveland, Ohio, United States

Site Status

Cleveland Clinic Taussing Cancer Center

Cleveland, Ohio, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Cleveland Clinic Taussing Cancer Center

Cleveland, Ohio, United States

Site Status

Inova Schar Cancer Institute Infusion Pharmacy

Fairfax, Virginia, United States

Site Status

Inova Schar Cancer Institute

Fairfax, Virginia, United States

Site Status

Seattle Cancer Care Alliance

Seattle, Washington, United States

Site Status

Seattle Cancer Care Alliance

Seattle, Washington, United States

Site Status

University of Washington Medical Center

Seattle, Washington, United States

Site Status

Centro de Investigacion Pergamino S.A.

Pergamino, Buenos Aires, Argentina

Site Status

Fundación CENIT para la Investigación en Neurociencias

CABA, , Argentina

Site Status

GP Diagnostico SRL

La Rioja, , Argentina

Site Status

Hospital Regional Dr. Enrique Vera Barros

La Rioja, , Argentina

Site Status

Instituto del Diagnostico

La Rioja, , Argentina

Site Status

Centro Oncologico Riojano Integral (Cori)

La Rioja, , Argentina

Site Status

Chris O'Brien Lifehouse

Camperdown, New South Wales, Australia

Site Status

Concord Hospital

Concord, New South Wales, Australia

Site Status

Dubbo Base Hospital

Dubbo, New South Wales, Australia

Site Status

Ramsay Pharmacy

Kogarah, New South Wales, Australia

Site Status

St George Private Hospital

Kogarah, New South Wales, Australia

Site Status

Epic Pharmacy

Lismore, New South Wales, Australia

Site Status

North Coast Radiology St Vincents

Lismore, New South Wales, Australia

Site Status

Northern Rivers Pathology Service

Lismore, New South Wales, Australia

Site Status

St Vincent's Pathology Lismore

Lismore, New South Wales, Australia

Site Status

Macquarie Medical Imaging

Macquarie University, New South Wales, Australia

Site Status

Macquarie University Hospital Pharmacy

Macquarie University, New South Wales, Australia

Site Status

Macquarie University

Macquarie University, New South Wales, Australia

Site Status

The Murwillumbah Hospital

Murwillubah, New South Wales, Australia

Site Status

The Tweed Hospital Pharmacy Department

Tweed Heads, New South Wales, Australia

Site Status

The Tweed Hospital

Tweed Heads, New South Wales, Australia

Site Status

Icon Cancer Care Wesley

Auchenflower, Queensland, Australia

Site Status

River City Pharmacy

Auchenflower, Queensland, Australia

Site Status

Oncology Pharmacy

Birtinya, Queensland, Australia

Site Status

Sunshine Coast University Hospital

Birtinya, Queensland, Australia

Site Status

Icon Cancer Care Chermside

Chermside, Queensland, Australia

Site Status

The Townsville Hospital

Douglas, Queensland, Australia

Site Status

Slade Health

Geebung, Queensland, Australia

Site Status

Icon Cancer Care South Brisbane

South Brisbane, Queensland, Australia

Site Status

Icon Cancer Care

South Brisbane, Queensland, Australia

Site Status

Integrated Clinical Oncology Network (ICON) Corporate Office

South Brisbane, Queensland, Australia

Site Status

Icon Cancer Care Southport

Southport, Queensland, Australia

Site Status

Flinders Medical Centre

Bedford Park, South Australia, Australia

Site Status

SA Pharmacy, Level 3 Pharmacy

Bedford Park, South Australia, Australia

Site Status

Adelaide Cancer Centre

Kurralta Park, South Australia, Australia

Site Status

Ashford Cancer Centre Research

Kurralta Park, South Australia, Australia

Site Status

Cancer Care SA Pty Ltd

Kurralta Park, South Australia, Australia

Site Status

Icon Cancer Care SA trading as Icon Pharmacy Adelaide

Kurralta Park, South Australia, Australia

Site Status

The Queen Elizabeth Hospital

Woodville South, South Australia, Australia

Site Status

BHS Diagnostic Services

Ballarat, Victoria, Australia

Site Status

Lake Imaging

Ballarat, Victoria, Australia

Site Status

Ballarat Oncology & Haematology Services

Ballarat, Victoria, Australia

Site Status

Box Hill Hospital - Pharmacy Department, Bulding B, Loading Dock (access via Thames St)

Box Hill, Victoria, Australia

Site Status

Box Hill Hospital

Box Hill, Victoria, Australia

Site Status

Eastern Health Clinical School

Box Hill, Victoria, Australia

Site Status

Monash Medical Centre

Clayton, Victoria, Australia

Site Status

Monash Medical Centre

East Bentleigh, Victoria, Australia

Site Status

Moorabbin Radiology

East Bentleigh, Victoria, Australia

Site Status

Ballarat Day Procedure Centre

Wendouree, Victoria, Australia

Site Status

Ballarat Oncology & Haematology Services

Wendouree, Victoria, Australia

Site Status

Nova Pharmacy

Wendouree, Victoria, Australia

Site Status

Fiona Stanley Hospital

Murdoch, Western Australia, Australia

Site Status

St John of God Murdoch Hospital

Murdoch, Western Australia, Australia

Site Status

Slade Health

Mount Waverley, , Australia

Site Status

Macquarie Heart

New South Wales, , Australia

Site Status

AZ Klina - Apotheek

Brasschaat, , Belgium

Site Status

AZ Klina

Brasschaat, , Belgium

Site Status

Hôpital Erasme

Brussels, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

AZ Groeninge

Kortrijk, , Belgium

Site Status

CHU de Liège

Liège, , Belgium

Site Status

GZA Sint-Augustinus

Wilrijk, , Belgium

Site Status

Hospital da Bahia

Salvador, Estado de Bahia, Brazil

Site Status

CENOB Centro de Oncologia da Bahia S/S Ltda. / Oncovida

Salvador, Estado de Bahia, Brazil

Site Status

Instituto Nacional de Câncer - INCA

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Associacao Hospital de Caridade Ijui

Ijuí, Rio Grande do Sul, Brazil

Site Status

ONCOSITE - Centro de Pesquisa Clinica em Oncologia

Ijuí, Rio Grande do Sul, Brazil

Site Status

Associação Educadora São Carlos - AESC / Hospital Mãe de Deus

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Ambulatório Quimioterapia

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Centro de Abastecimento Farmaceut

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Farmácia Oncológica

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Associação Educadora São Carlos - AESC / Hospital Mãe de Deus

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Mãe de Deus/Aesc

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Uniao Brasileira de Educacao e Assistencia / Hospital Sao Lucas da PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Fundação FPio XII Barretos

Barretos, São Paulo, Brazil

Site Status

Fundação Pio XII Barretos

Barretos, São Paulo, Brazil

Site Status

Centro Integrado de Pesquisa Clinica - CIP

São José do Rio Preto, São Paulo, Brazil

Site Status

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

São José do Rio Preto, São Paulo, Brazil

Site Status

Fundacao Faculdade de Medicina / Instituto do Cancer do Estado de Sao Paulo - ICESP

São Paulo, São Paulo, Brazil

Site Status

Sociedade Beneficente de Senhoras Hospital Sírio Libanês

São Paulo, São Paulo, Brazil

Site Status

Sociedade Beneficente de Senhoras Hospital Sírio Libanês

São Paulo, São Paulo, Brazil

Site Status

Hospital Alemao Oswaldo Cruz

São Paulo, São Paulo, Brazil

Site Status

Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP

São Paulo, São Paulo, Brazil

Site Status

Hospital Israelita Albert Einstein - SP

São Paulo, São Paulo, Brazil

Site Status

Sociedade Beneficente de Senhoras Hospital Sírio Libanês/ Instituo Sirio Libanes de Ensino e Pesqu

São Paulo, , Brazil

Site Status

William Osler Health System

Brampton, Ontario, Canada

Site Status

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Site Status

CHUM - Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, Canada

Site Status

Fakultni nemocnice u sv. Anny v Brne

Brno, Ceska Republika, Czechia

Site Status

Fakultni nemocnice Brno

Brno, , Czechia

Site Status

Fakultni nemocnice u sv. Anny v Brne

Brno, , Czechia

Site Status

Fakultni nemocnice u sv.Anny v Brne

Brno, , Czechia

Site Status

Nemocnice Horovice, NH Hospital a.s.

Hořovice, , Czechia

Site Status

Nemocnice Horovice

Hořovice, , Czechia

Site Status

Aalborg Universitetshospital Syd

Aalborg, , Denmark

Site Status

Aalborg Universitetshospital

Aalborg, , Denmark

Site Status

Sygehusapoteket Aalborg

Aalborg, , Denmark

Site Status

Aarhus Universitetshospital

Aarhus C, , Denmark

Site Status

Aarhus Universitetshospital

Aarhus N, , Denmark

Site Status

CT-Klinikken A/S

Aarhus N, , Denmark

Site Status

Rigshospitalet, Onkologisk Klinik, afsnit 5073

Copenhagen OE, , Denmark

Site Status

Herlev Hospital

Herlev, , Denmark

Site Status

Herlev og Gentofte Hospital

Herlev, , Denmark

Site Status

Klinik for Klinisk Fysiologi,Nuklearmedicin og PET

København Ø, , Denmark

Site Status

Rigshospitalet

København Ø, , Denmark

Site Status

Odense Universitetshospital

Odense, , Denmark

Site Status

Odense Universitetshospital

Odense C, , Denmark

Site Status

Groupe hospitalier Pitie Saleptriere

Paris, Cedex 13, France

Site Status

Institut de cancérologie de l'Ouest - Site Paul Papin

Angers, , France

Site Status

Institut de cancérologie de l'Ouest - Site Paul Papin

Angers, , France

Site Status

Centre d'Oncologie et de Radiothérapie du Pays-Basque

Bayonne, , France

Site Status

Clinique CAPIO Belharra

Bayonne, , France

Site Status

CHU Besançon - Pharmacie Unite Essais cliniques

Besançon, , France

Site Status

CHU Besançon

Besançon, , France

Site Status

Hôpital Jean Minjoz

Besançon, , France

Site Status

Hôpital Henri Mondor

Créteil, , France

Site Status

Hôpital Privé Toulon-Hyères - Clinique Sainte Marguerite

Hyères, , France

Site Status

Clinique Victor Hugo

Le Mans, , France

Site Status

Centre Oscar Lambret

Lille, , France

Site Status

Centre Oscar Lambret

Lille, , France

Site Status

Centre Leon Berard

Lyon, , France

Site Status

Centre Léon Berard

Lyon, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

Hopital La Conception

Marseille, , France

Site Status

Hopital de La Timone

Marseille, , France

Site Status

Hopital de La Timone

Marseille, , France

Site Status

CHU Nimes - Hopital Caremeau

Nîmes, , France

Site Status

CHU Nimes - Institut de Cancerologie du Gard

Nîmes, , France

Site Status

CHU Nimes

Nîmes, , France

Site Status

Groupe Hospitalier Pitié Salpêtrière

Paris, , France

Site Status

Groupe Hospitalier Pitié Salpêtrière

Paris, , France

Site Status

Centre Eugene Marquis

Rennes, , France

Site Status

CHU de Rouen - Hôpital Charles Nicolle

Rouen, , France

Site Status

CHU de Rouen

Rouen, , France

Site Status

Centre Henri Becquerel

Rouen, , France

Site Status

Institut de Cancérologie de l'Ouest - Centre René Gauducheau

Saint-Herblain, , France

Site Status

Centre de Radiothérapie - Clinique Sainte Anne

Strasbourg, , France

Site Status

Clinique Sainte Anne

Strasbourg, , France

Site Status

Hopital Foch -Pharmacie

Suresnes, , France

Site Status

Hopital Foch

Suresnes, , France

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

Medical Center of Athens

Marousi, Athens, Greece

Site Status

Metropolitan General Hospital

Athens, PC, Greece

Site Status

Sotiria General Chest Disease Hospital

Athens, , Greece

Site Status

Alexandra General Hospital, Oncology Department

Athens, , Greece

Site Status

University General Hospital of Patras, Division of Oncology

Pátrai, , Greece

Site Status

EUROMEDICA General Clinic of Thessaloniki

Thessaloniki, , Greece

Site Status

Department of Clinical Oncology

Hong Kong, , Hong Kong

Site Status

Kaposvári Egyetem Egészségügyi Centrum

Kaposvár, , Hungary

Site Status

Somogy Megyei Kaposi Mór Oktató Kórház

Kaposvár, , Hungary

Site Status

CIMS Cancer, Care Institute of Medical Sciences, CIMS Hospital

Ahmedabad, Gujarat, India

Site Status

Sahyadri Super Speciality Hospital

Pune, Maharashtra, India

Site Status

Dr Ram Manohar Lohia (RML) Hospital & PGI MER

New Delhi, National Capital Territory of Delhi, India

Site Status

Apollo Hospitals

Hyderabad, Telangana, India

Site Status

Medica Superspecialty hospital

Kolkata, West Bengal, India

Site Status

Rajiv Gandhi Cancer Institute And Research Centre

Delhi, , India

Site Status

Hadassah University Hospital

Kiryat Hadassah, Jerusalem, Israel

Site Status

The Chaim Sheba Medical Center

Tel Litwinsky, Ramat - GAN, Israel

Site Status

Assaf Harofe MC

Beer Yaakov, , Israel

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

The Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Farmacia Ospedaliera

Candiolo, (torino), Italy

Site Status

AOU Ospedali Riuniti di Ancona

Torrette, Ancona, Italy

Site Status

U.O. Anatomia Patologica

Forlì, Forli-cesena, Italy

Site Status

U.O. Radiologia

Forlì, Forli-cesena, Italy

Site Status

U.O.S. Medicina Nucleare

Forlì, Forli-cesena, Italy

Site Status

Farmacia Oncologica

Meldola, Forli-cesena, Italy

Site Status

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

Meldola, Forli-cesena, Italy

Site Status

U.O.C. Farmacia

Genova, Genoa, Italy

Site Status

IRCCS Ospedale Policlinico San Martino

Genoa, Liguria, Italy

Site Status

Farmacia Studi Clinici

Rozzano, Milan, Italy

Site Status

Istituto Clinico Humanitas

Rozzano, Milan, Italy

Site Status

AUSL della Romagna - RAVENNA, Presidio Ospedaliero di Faenza

Faenza, Ravenna, Italy

Site Status

Presidio Ospedaliero di Lugo

Lugo, Ravenna, Italy

Site Status

Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo

Candiolo, Torino, Italy

Site Status

Farmacia Ospedaliera

Arezzo, , Italy

Site Status

Presidio Ospedaliero San Donato

Arezzo, , Italy

Site Status

Centro di Riferimento Oncologico - IRCCS

Aviano (PN), , Italy

Site Status

S.O.C. di Farmacia

Aviano (PN), , Italy

Site Status

Azienda Ospedaliero-Universitaria Policlinico S.Orsola Malpighi

Bologna, , Italy

Site Status

U.O. Farmacia Clinica - IDS

Bologna, , Italy

Site Status

Fondazione IRCCS Istituto Nazionale Dei Tumori

Milan, , Italy

Site Status

SC Farmacia

Milan, , Italy

Site Status

Instituto Europeo di Oncologia

Milan, , Italy

Site Status

Servizio di Farmacia

Milan, , Italy

Site Status

Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"

Naples, , Italy

Site Status

UOSC Farmacia

Naples, , Italy

Site Status

Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale

Napoli, , Italy

Site Status

S.C. Farmacia Ospedaliera

Napoli, , Italy

Site Status

A.O.U. Pisana Ospedale S. Chiara

Pisa, , Italy

Site Status

Presidio Ospedaliero di Ravenna

Ravenna, , Italy

Site Status

Servizio Farmacia Ospedaliera - Farmacia Oncologica

Ravenna, , Italy

Site Status

Azienda Ospedaliera San Camillo Forlanini_Oncologia Medica

Rome, , Italy

Site Status

U.O.C. Farmacia

Rome, , Italy

Site Status

Azienda Ospedaliera S. Maria di Terni

Terni, , Italy

Site Status

S.C. Farmacia Interna

Terni, , Italy

Site Status

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Hirosaki University School of Medicine & Hospital

Hirosaki, Aomori, Japan

Site Status

National Hospital Organization Shikoku Cancer Center

Matsuyama, Ehime, Japan

Site Status

Gunma Prefectural Cancer Center

Ōta, Gunma, Japan

Site Status

National Hospital Organization hokkaido Cancer Center

Sapporo, Hokkaido, Japan

Site Status

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

Site Status

Kobe City Medical Center General Hospital

Kobe, Hyōgo, Japan

Site Status

Tsukuba Medical Center Hospital

Tsukuba, Ibaraki, Japan

Site Status

Iwate Medical University Hospital

Shiwa-gun, Iwate, Japan

Site Status

National Hospital Organization Sagamihara National Hospital

Sagamihara, Kanagawa, Japan

Site Status

Kanagawa cancer center

Yokohama, Kanagawa, Japan

Site Status

Kindai University Hospital

Sayama, Osaka, Japan

Site Status

Saitama Medical University International Medical Center

Hidaka, Saitama, Japan

Site Status

Dokkyo Medical University Saitama Medical Center

Koshigaya, Saitama, Japan

Site Status

Hamamatsu University School of Medicine, University Hospital

Hamamatsu, Shizuoka, Japan

Site Status

Nihon University Itabashi Hospital

Itabashi-ku, Tokyo, Japan

Site Status

The Cancer Institute Hospital of JFCR

Koto-Ku, Tokyo, Japan

Site Status

Keio University Hospital

Shinjuku-Ku, Tokyo, Japan

Site Status

Yamaguchi University Hospital

Ube, Yamaguchi, Japan

Site Status

Chiba Cancer Center

Chiba, , Japan

Site Status

National Hospital Organization Kyushu Cancer Center

Fukuoka, , Japan

Site Status

Kyushu University Hospital

Fukuoka, , Japan

Site Status

Hiroshima City Hiroshima Citizens Hospital

Hiroshima, , Japan

Site Status

Kagoshima University Hospital

Kagoshima, , Japan

Site Status

National Hospital Organization Kumamoto Medical Center

Kumamoto, , Japan

Site Status

Niigata University Medical & Dental Hospital

Niigata, , Japan

Site Status

Osaka City University Hospital

Osaka, , Japan

Site Status

Tokushima University Hospital

Tokushima, , Japan

Site Status

Yamagata University Hospital

Yamagata, , Japan

Site Status

Hospital Médica Campestre (Administradora Hospitalaria S.A de C.V.)

León, Guanajuato, Mexico

Site Status

Centro de Investigación Clínica de Leon S.C.

León, Guanajuato, Mexico

Site Status

Instituto Nacional de Cancerologia

Mexico City, Mexico City, Mexico

Site Status

Phylasis Clinicas Research S. de R.L. de C.V.

Cuautitlán Izcalli, State of Mexico, Mexico

Site Status

Rijnstate Arnhem

Arnhem, , Netherlands

Site Status

Ziekenhuis Rijnstate

Arnhem, , Netherlands

Site Status

St Apotheek der Haarlemse Ziekenhuizen

Haarlem, , Netherlands

Site Status

Spaarne Gasthuis

Hoofddorp, , Netherlands

Site Status

Maastricht University Medical Center

Maastricht, , Netherlands

Site Status

Radboud University Medical Center

Nijmegen, , Netherlands

Site Status

Radboudumc

Nijmegen, , Netherlands

Site Status

Auckland City Hospital Pharmacy

Grafton, Auckland, New Zealand

Site Status

Auckland City Hospital

Grafton, Auckland, New Zealand

Site Status

Slade Health Inward Goods

Auckalnd, , New Zealand

Site Status

Christchurch Hospital

Christchurch, , New Zealand

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Akershus University Hospital

Lorenskog, , Norway

Site Status

Sykehusapoteket HF 23 Lørenskog

Lorenskog, , Norway

Site Status

Sykehusapoteket HF 23 Lørenskog

Nordbyhagen, , Norway

Site Status

Sykehusapoteket Lorenskog

Nordbyhagen, , Norway

Site Status

Bildediagnostisk avdeling

Nordbyhagen, , Norway

Site Status

Stavanger University Hospital

Stavanger, , Norway

Site Status

Centralny Szpital Kliniczny MSWiA w Warszawie

Warsaw, Masovian Voivodeship, Poland

Site Status

Centralny Szpital Kliniczny MSWiA

Warsaw, Masovian Voivodeship, Poland

Site Status

Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli

Lublin, , Poland

Site Status

Lecznice CITOMED Sp. z o.o.

Torun, , Poland

Site Status

Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Obserwacyjno-Zakazny

Torun, , Poland

Site Status

Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu

Torun, , Poland

Site Status

Wojewodzki Szpital Zespolony im. L. Rydygiera, Szpital Specjalistyczny dla Dzieci I Doroslych

Torun, , Poland

Site Status

Instituto Português de Oncologia de Coimbra Francisco Gentil, EPE

Coimbra, , Portugal

Site Status

Hospital Da Luz Coimbra, SA

Coimbra, , Portugal

Site Status

Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos

Lisbon, , Portugal

Site Status

Hospital CUF Descobertas, SA

Lisbon, , Portugal

Site Status

Dr. Campos Costa - Consultório de Tomografia Computorizada, S.A.

Porto, , Portugal

Site Status

Instituto Português de Oncologia do Porto Francisco Gentil, EPE

Porto, , Portugal

Site Status

Centro Hospitalar de São João, EPE

Porto, , Portugal

Site Status

Dr. Campos Costa - Consultório de Tomografia Computorizada, S.A.- Matosinhos

Senhora da Hora, , Portugal

Site Status

Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE

Vila Real, , Portugal

Site Status

State Budgetary Healthcare Insti. Republican Clinical Oncology Dispensary of the MoH of Bashk. Rep.

Ufa, Bashkortostan Republic, Russia

Site Status

Federal State Budgetary Institution "National medical research radiology center" MoH RF

Obninsk, Kaluga Oblast, Russia

Site Status

Private Medical Institution "Evromedservice"

Pushkin, Sankt-Peterburg, Russia

Site Status

Principal Military Clinical Hospital n.a. N.N. Burdenko

Moscow, , Russia

Site Status

Moscow Research Oncology Institute named after P. A. Gertsen

Moscow, , Russia

Site Status

BHI of Omsk region "Clinical oncological dispensary"

Omsk, , Russia

Site Status

FGBIH "Clinical Hospital #122 n.a. L.G. Sokolov of Federal Medico-biological agency"

Saint Petersburg, , Russia

Site Status

Non-State Healthcare Institution "Railway Clinical Hospital JSC RZhD"

Saint Petersburg, , Russia

Site Status

FSBEI HE "First St. Petersburg State Medical University n. a. academician l.P Pavlov" MoH RF

Saint Petersburg, , Russia

Site Status

FSBEI HE "First St. Petersburg State Medical University n.a. academician I.P Pavlov" MoH RF

Saint Petersburg, , Russia

Site Status

FSBEI HE "First St. Petersburg State Medical University n.a. academician I.P Pavlov"

Saint Petersburg, , Russia

Site Status

"Ramsay Diagnostics Rus", LLC

Saint Petersburg, , Russia

Site Status

FSBI "Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov

Saint Petersburg, , Russia

Site Status

Hospital Orkli, LLC

Saint Petersburg, , Russia

Site Status

Mart, Llc

Saint Petersburg, , Russia

Site Status

SHI YR "Regional Clinical Oncology Hospital"

Yaroslavl, , Russia

Site Status

Institute for Oncology and Radiology of Serbia

Belgrade, , Serbia

Site Status

Oncology Institute of Vojvodina

Kamenitz, , Serbia

Site Status

Clinical Centre Nis, Clinic of Oncology

Niš, , Serbia

Site Status

National Cancer Center - Clinical Trial Pharmacy

Goyang-si, Gyeonggi-do, South Korea

Site Status

National Cancer Center Urology center for Prostate Cancer

Goyang-si, Gyeonggi-do, South Korea

Site Status

Seoul National University Bundang Hospital, Clinical Pharmacy

Seongnam-si, Gyeonggido, South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggido, South Korea

Site Status

Chungnam National University Hospital, Clinical Pharmacy

Daejeon, , South Korea

Site Status

Chungnam National University Hospital

Daejeon, , South Korea

Site Status

Severance Hospital Yonsei University Health System

Seoul, , South Korea

Site Status

Asan Medical Center - Clinical Trial Pharmacy

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Samsung Medical Center Clinical Trial Pharmacy

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

C.H. Univ. Santiago de Compostela

Santiago de Compostela, A Coruña, Spain

Site Status

Hospital Comarcal General de Elda de Virgen de la Salud

Elda, Alicante, Spain

Site Status

Hospital Universitario Germans Trias i Pujol

Badalona, Barcelona, Spain

Site Status

Institut Catalá d'Oncología - Hospital Duran i Reynals

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Institut Catalá d'Oncología

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Althaia. Xarxa Assistencial Universitaria de Manresa

Manresa, Barcelona, Spain

Site Status

Corporacio Sanitaria Parc Tauli

Sabadell, Barcelona, Spain

Site Status

C. H. Universitario de Vigo- Hospital Álvaro Cunqueiro

Vigo, Galicia, Spain

Site Status

C. H. Universitario de Vigo- Hospital Álvaro Cunqueiro

Vigo, Galicia, Spain

Site Status

C.H. Universitario de Vigo- Hospital Meixoeiro

Vigo, Galicia, Spain

Site Status

Hospital Universitario Infanta Sofia

San Sebastián de los Reyes, Madrid, Spain

Site Status

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Site Status

Complejo Hospitalario de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, Spain

Site Status

Hospital General Universitario de Elche

Elche, Valencia, Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, Valencia, Spain

Site Status

Hospital Vithas Internacional Medimar

Alicante, , Spain

Site Status

Hospital Universitario Infanta Cristina

Badajoz, , Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hospital Quiron of Barcelona

Barcelona, , Spain

Site Status

Hospital Quiron

Barcelona, , Spain

Site Status

Hospital Quirón de Barcelona

Barcelona, , Spain

Site Status

Hospital de La Santa Creu i Sant pau_Oncology department

Barcelona, , Spain

Site Status

Hospital de La Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

CETIR Grup Medic

Barcelona, , Spain

Site Status

Cetir, Centre Mèdic, S.L

Barcelona, , Spain

Site Status

Hospital de Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Laboratorio Dr. F. Echevarne Analisis, S.A

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia

Córdoba, , Spain

Site Status

Hospital Universitario Reina Sofía

Córdoba, , Spain

Site Status

H. univ Girona Dr. Josep Trueta - lnstitut Catala d'Oncologia

Girona, , Spain

Site Status

Institut Catala d'Oncologia

Girona, , Spain

Site Status

Institut Diagnostic de la lmatge

Girona, , Spain

Site Status

Hospital Universitario Lucus Augusti

Lugo, , Spain

Site Status

Fundacion Maria Rafols para la investigacion del Diagnostico de la imagen

Madrid, , Spain

Site Status

Gabinete Radiologico Doctor Pita

Madrid, , Spain

Site Status

Hospital General Universitario Gregorio Marañon

Madrid, , Spain

Site Status

Hospital Ruber Internacional

Madrid, , Spain

Site Status

Hospital Ruber International

Madrid, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Clínico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Universitario HM Sanchinarro - CIOCC

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocio

Seville, , Spain

Site Status

Instituto Valenciano de Oncología

Valencia, , Spain

Site Status

Hospital Clínico Universitario de Valencia

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Site Status

APL

Stockholm, , Sweden

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

Clinical Trial Pharmacy, China Medical University Hospital

Taichung, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Department of Pharmacy, National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

Investigational Drug services, National Taiwan University Hospital

Taipei, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Koo Foundation Sun Yat-Sen Cancer Center

Taipei, , Taiwan

Site Status

Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital, Linkou

Taoyuan District, , Taiwan

Site Status

Chemotherapy pharmacy, Chang Gung Memorial Hospital, Linkou

Taoyuan District, , Taiwan

Site Status

Royal United Hospitals Bath NHS Foundation Trust

Bath, , United Kingdom

Site Status

St Bartholomew 's Hospital, Barts Health NHS Trust

London, , United Kingdom

Site Status

St. Bartholomew's Hospital, Barts Health NHS Trust

London, , United Kingdom

Site Status

Guy's & St. Thomas' NHS Foundation Trust

London, , United Kingdom

Site Status

Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital

London, , United Kingdom

Site Status

Churchill Hospital, Oxford University Hospitals NHS Trust

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Canada Czechia Denmark France Greece Hong Kong Hungary India Israel Italy Japan Mexico Netherlands New Zealand Norway Poland Portugal Russia Serbia South Korea Spain Sweden Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Vashistha R, Noor Z, Dasgupta S, Pu J, Deng S. Application of statistical machine learning in biomarker selection. Sci Rep. 2023 Oct 26;13(1):18331. doi: 10.1038/s41598-023-45323-9.

Reference Type DERIVED
PMID: 37884606 (View on PubMed)

Bellmunt J, Chang J, Pavilack-Kirker M, Cappelleri JC, Costa N, Esterberg E, Kearney M, Hitchens A, Candrilli SD, Ajmera M. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review. Clin Genitourin Cancer. 2023 Aug;21(4):459-466. doi: 10.1016/j.clgc.2023.03.011. Epub 2023 Mar 31.

Reference Type DERIVED
PMID: 37149458 (View on PubMed)

Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullen A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol. 2023 Jul;84(1):95-108. doi: 10.1016/j.eururo.2023.03.030. Epub 2023 Apr 28.

Reference Type DERIVED
PMID: 37121850 (View on PubMed)

Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullen A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J, Aragon-Ching JB, Wang J, Huang B, Laliberte RJ, di Pietro A, Grivas P. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up. J Clin Oncol. 2023 Jul 1;41(19):3486-3492. doi: 10.1200/JCO.22.01792. Epub 2023 Apr 18.

Reference Type DERIVED
PMID: 37071838 (View on PubMed)

Lee JL, Desai C, Park SH, Tsuchiya N, Su PJ, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Eto M. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis. Urol Oncol. 2023 May;41(5):256.e17-256.e25. doi: 10.1016/j.urolonc.2023.02.002. Epub 2023 Apr 3.

Reference Type DERIVED
PMID: 37019764 (View on PubMed)

Grivas P, Kopyltsov E, Su PJ, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C, Climent Duran MA, Bamias A, Caserta C, Chang J, Cislo P, di Pietro A, Wang J, Powles T. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. Eur Urol. 2023 Apr;83(4):320-328. doi: 10.1016/j.eururo.2022.04.016. Epub 2022 May 30.

Reference Type DERIVED
PMID: 35654659 (View on PubMed)

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullen A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte RJ, Huang B, Costa N, Blake-Haskins JA, Grivas P. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future Oncol. 2022 Jun;18(19):2361-2371. doi: 10.2217/fon-2021-1631. Epub 2022 Apr 13.

Reference Type DERIVED
PMID: 35416053 (View on PubMed)

Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Powles T, Yoshida M, Koide Y, Umeyama Y, di Pietro A, Uemura H. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. Int J Clin Oncol. 2022 Feb;27(2):383-395. doi: 10.1007/s10147-021-02067-8. Epub 2022 Jan 1.

Reference Type DERIVED
PMID: 34973108 (View on PubMed)

Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R, Dourthe LM, Alvarez-Fernandez C, Aarts M, di Pietro A, Grivas P, Davis CB. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med. 2021 Dec;27(12):2200-2211. doi: 10.1038/s41591-021-01579-0. Epub 2021 Dec 10.

Reference Type DERIVED
PMID: 34893775 (View on PubMed)

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullen A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.

Reference Type DERIVED
PMID: 32945632 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=B9991001

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-003262-86

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

JAVELIN BLADDER 100

Identifier Type: OTHER

Identifier Source: secondary_id

B9991001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SOGUG-AVELUMAB_RWD
NCT05700344 COMPLETED